On March 3, 2026, the U.S. Food and Drug Administration (FDA) announced a public consultation requesting comments on its Scale-Up and Postapproval Changes (SUPAC) guidances for pharmaceutical products. The consultation focuses on chemistry, manufacturing, and controls (CMC) requirements and aims to evaluate whether existing SUPAC guidance documents remain relevant and aligned with current scientific and regulatory standards.
The review covers SUPAC guidances for immediate release, modified release, and nonsterile semisolid dosage forms, as well as changes related to manufacturing equipment. Stakeholders across the pharmaceutical industry are invited to submit feedback to help determine whether revisions, clarifications, or additional topics should be incorporated into updated guidance.
The consultation period remains open until June 1, 2026.
Details of the Update
The FDA is seeking feedback on the utility, clarity, and applicability of current SUPAC guidances that address manufacturing scale-up and postapproval changes in pharmaceutical products.
The review specifically examines whether existing guidance documents for immediate release, modified release, and nonsterile semisolid dosage forms continue to support effective regulatory oversight of CMC changes. The agency is also evaluating guidance related to manufacturing equipment changes, which may impact manufacturing processes and quality systems.
In addition, the FDA is considering whether these documents remain aligned with more recent international regulatory frameworks, particularly ICH Q9(R1) on Quality Risk Management and ICH Q12 on Pharmaceutical Product Lifecycle Management. The agency is encouraging stakeholders to identify challenges in interpreting or implementing SUPAC recommendations within their current pharmaceutical quality systems.
Industry participants may also suggest new topics, updates, or revisions that could improve the relevance of the guidance while helping reduce regulatory complexity or unnecessary burden.
Feedback Deadline
Stakeholders are invited to submit comments on the FDA’s SUPAC guidance review by June 1, 2026. Submissions may be made through the electronic or written channels specified by the FDA.
Why It Matters
SUPAC guidances play an important role in defining how pharmaceutical manufacturers manage postapproval changes in manufacturing and quality control processes. By reviewing these documents, the FDA aims to ensure they reflect current scientific standards, risk-based regulatory approaches, and alignment with international frameworks such as ICH Q9(R1) and ICH Q12.
Updating these guidances may support greater regulatory clarity, digital alignment in quality systems, and efficient lifecycle management of pharmaceutical products, while minimizing unnecessary regulatory burden for manufacturers.
Who This Is Relevant For
This consultation is particularly relevant for regulatory affairs teams, quality assurance (QA) professionals, manufacturing and CMC specialists, and pharmaceutical compliance leaders responsible for managing scale-up activities and postapproval changes within regulated pharmaceutical manufacturing environments.
Next Steps
Organizations should review their current internal procedures for managing scale-up and postapproval manufacturing changes against the existing SUPAC guidances. Regulatory and quality teams may consider identifying areas where clarification, modernization, or additional guidance would improve implementation or reduce operational complexity.
Companies may also benefit from coordinating cross-functional feedback across regulatory, quality, and manufacturing teams to develop a comprehensive response before submitting comments to the FDA prior to the June 1, 2026 deadline.
As regulatory expectations around CMC lifecycle management and risk-based change control continue to evolve, regulatory intelligence and monitoring tools can help organizations track consultations and anticipate potential regulatory shifts.
RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.
FAQs
What is the FDA requesting feedback in the SUPAC consultation?
The FDA is requesting public comments on the relevance, clarity, and usefulness of existing SUPAC guidances that address scale-up and postapproval changes for pharmaceutical products, particularly in the context of chemistry, manufacturing, and controls (CMC).
Which pharmaceutical product categories are covered in the SUPAC review?
The consultation covers SUPAC guidances for immediate release, modified release, and nonsterile semisolid dosage forms, as well as guidance related to manufacturing equipment changes.
When is the deadline to submit comments to the FDA?
Stakeholders must submit comments on the SUPAC guidance review by June 1, 2026, using the electronic or written submission channels specified by the FDA.
How can RegASK help companies monitor regulatory updates related to infant formulas?
RegASK helps regulatory and compliance teams monitor global regulatory updates, analyze potential impacts, and coordinate internal responses to consultations and guidance revisions. Its agentic AI-powered regulatory intelligence platform enables organizations to track evolving regulatory frameworks, assess compliance risks, and streamline collaboration across regulatory, quality, and manufacturing teams.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
